Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Bladder Cancer, April 2024

Free Subscription


Abstracts

Retrieve all available abstracts of the following 209 articles:
HTML format


 

Single Articles

  1. INTERNATIONAL BR
    Retracted: lncRNA MIR4435-2HG Accelerates the Development of Bladder Cancer through Enhancing IQGAP3 and CDCA5 Expression.
    Biomed Res Int. 2024;2024:9783095.
    PubMed    
    Abstract available

  2. WU S, Li G, Ouyang W, Tian Y, et al
    Ferrous Selenide Stabilized Black Phosphorus Heterojunction Sonosensitizer for MR Imaging-Guided Sonodynamic Therapy of Bladder Cancer.
    Biomater Res. 2024;28:0014.
    PubMed    
    Abstract available

  3. LI G, Wu S, Liu J, Wang K, et al
    Narrow Bandgap Schottky Heterojunction Sonosensitizer with High Electron-Hole Separation Boosted Sonodynamic Therapy in Bladder Cancer.
    Adv Mater. 2024 Mar 28:e2401252. doi: 10.1002/adma.202401252.
    PubMed    
    Abstract available

  4. LIM Y, Park J, Lim JE, Park M, et al
    Evaluating a combination treatment of NK cells and reovirus against bladder cancer cells using an in vitro assay to simulate intravesical therapy.
    Sci Rep. 2024;14:7390.
    PubMed    
    Abstract available

  5. ZHANG X, Guo J, Yun Y, Shan D, et al
    Differentiation of Muscular Invasion in Bladder Cancer: Additional Value of Synthetic Magnetic Resonance Imaging.
    Acad Radiol. 2024 Mar 27:S1076-6332(24)00153-3. doi: 10.1016/j.acra.2024.
    PubMed    
    Abstract available

  6. JIANG C, Li X, Chen R, Yang Y, et al
    Enzyme-labeled liquid-based cytology (ELLBC): a new noninvasive diagnostic method for bladder cancers.
    J Cancer Res Clin Oncol. 2024;150:169.
    PubMed    
    Abstract available


  7. Retraction: 'ASPM predicts poor prognosis and regulates cell proliferation in bladder cancer'. Zhen-Ya Gao, Fang Yu, Huan-Xia Jia, Zhuo Ye, Shi-Jie Yao, Kaohsiung J Med Sci. 2020; 36: 1021-1029 (https://doi.org/10.1002/kjm2.12284).
    Kaohsiung J Med Sci. 2024 Mar 28. doi: 10.1002/kjm2.12825.
    PubMed    
    Abstract available

  8. NANDANA PI, Rasyid H, Prihantono P, Yustisia I, et al
    Cytotoxicity and Apoptosis Studies of Brucein D against T24 Bladder Cancer Cells.
    Asian Pac J Cancer Prev. 2024;25:921-930.
    PubMed    
    Abstract available

  9. KDIMATI S, Christoph C, Glass A, Engel N, et al
    Differential Expression of CKLF-like MARVEL Transmembrane Domain-Containing Protein 6 and Programmed Cell Death Ligand 1 as Prognostic Biomarkers in Upper Tract Urothelial Carcinoma.
    Int J Mol Sci. 2024;25:3492.
    PubMed    
    Abstract available

  10. VIKERFORS A, Davidsson S, Carlsson J, Jerlstrom T, et al
    Plasma Levels of Pentraxin 3: A Potential Prognostic Biomarker in Urinary Bladder Cancer Patients.
    Int J Mol Sci. 2024;25:3473.
    PubMed    
    Abstract available

  11. FERREIRA E, Ferreira D, Relvas-Santos M, Freitas R, et al
    Aberrantly Glycosylated GLUT1 as a Poor Prognosis Marker in Aggressive Bladder Cancer.
    Int J Mol Sci. 2024;25:3462.
    PubMed    
    Abstract available

  12. PEREIRA F, Domingues MR, Vitorino R, Guerra IMS, et al
    Unmasking the Metabolite Signature of Bladder Cancer: A Systematic Review.
    Int J Mol Sci. 2024;25:3347.
    PubMed    
    Abstract available

  13. SHIN J, Park JW, Kim SY, Lee JH, et al
    Strategies for Overcoming Immune Evasion in Bladder Cancer.
    Int J Mol Sci. 2024;25:3105.
    PubMed    
    Abstract available

  14. OTOSHI T, Yamasaki T, Matsue T, Yukimatsu N, et al
    Comparison of Oncological Outcomes between Transperitoneal and Retroperitoneal Approaches in Laparoscopic Nephroureterectomies for Upper Tract Urothelial Carcinoma.
    Medicina (Kaunas). 2024;60:421.
    PubMed    
    Abstract available

  15. DA PRAT V, Aretano L, Moschini M, Bettiga A, et al
    Effectiveness of Preoperative Immunonutrition in Improving Surgical Outcomes after Radical Cystectomy for Bladder Cancer: Study Protocol for a Multicentre, Open-Label, Randomised Trial (INu-RC).
    Healthcare (Basel). 2024;12:696.
    PubMed    
    Abstract available

  16. PEREIRA M, Vale N
    Exploring Darunavir, Rilpivirine and Etravirine as Potential Therapies for Bladder Cancer: Efficacy and Synergistic Effects.
    Biomedicines. 2024;12:647.
    PubMed    
    Abstract available

  17. DUGBARTEY GJ, Relouw S, McFarlane L, Sener A, et al
    Redox System and Oxidative Stress-Targeted Therapeutic Approaches in Bladder Cancer.
    Antioxidants (Basel). 2024;13:287.
    PubMed    
    Abstract available

  18. DUEX J, Theodorescu D
    CD44 in Bladder Cancer.
    Cancers (Basel). 2024;16:1195.
    PubMed    
    Abstract available

  19. AL-MARSOUMMI S, Mehus AA, Garrett SH, Sens DA, et al
    The Effect of Retinoic Acid on Arsenite-Transformed Malignant UROtsa Bladder Cancer Cells: In Vitro Model of Basal Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2024;16:1178.
    PubMed    
    Abstract available


  20. [Not Available].
    Aktuelle Urol. 2024;55:100-102.
    PubMed    


  21. LV Z, Hou J, Wang Y, Wang X, et al
    Reply to "Knowledge-map analysis and bladder cancer immunotherapy: Comment".
    Hum Vaccin Immunother. 2024;20:2325756.
    PubMed    


  22. URABE F, Tsuzuki S, Kimura T
    Letter to the editor for the article "Nephron-sparing ureteroscopic surgery vs. radical nephroureterectomy: comparable survival-outcomes in upper tract urothelial carcinoma".
    World J Urol. 2024;42:198.
    PubMed    


  23. JOHN H
    [BCG instillation sepsis in bladder carcinoma].
    Praxis (Bern 1994). 2024;113:44.
    PubMed    


  24. BARBOS V, Feciche B, Latcu S, Croitor A, et al
    The Assessment of SF-36 Survey for Quality-of-Life Measurement after Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Systematic Review.
    Diseases. 2024;12:56.
    PubMed    
    Abstract available

  25. SANGUEDOLCE F, Falagario UG, Zanelli M, Palicelli A, et al
    Prognostic Value of P63 Expression in Muscle-Invasive Bladder Cancer and Association with Molecular Subtypes-Preliminary Report.
    Curr Issues Mol Biol. 2024;46:2456-2467.
    PubMed    
    Abstract available

  26. RAHMAN KMM, Kumbham S, Bist G, Woo S, et al
    Comparison of red and green light for treating non-muscle invasive bladder cancer in rats using singlet oxygen-cleavable prodrugs with PPIX-PDT.
    Photochem Photobiol. 2024 Mar 27. doi: 10.1111/php.13933.
    PubMed    
    Abstract available

  27. DU L, Wang B, Wen J, Zhang N, et al
    Examining the causal association between psoriasis and bladder cancer: A two-sample Mendelian randomization analysis.
    Skin Res Technol. 2024;30:e13663.
    PubMed    
    Abstract available

  28. GERCEK O, Senkol M, Yazar VM, Topal K, et al
    The Effect of Lymphovascular Invasion on Short-Term Tumor Recurrence and Progression in Stage T1 Bladder Cancer.
    Cureus. 2024;16:e54844.
    PubMed    
    Abstract available

  29. KONG T, Qu Y, Zhao T, Niu Z, et al
    Identification of novel protein biomarkers from the blood and urine for the early diagnosis of bladder cancer via proximity extension analysis.
    J Transl Med. 2024;22:314.
    PubMed    
    Abstract available

  30. TANG C, Fan Y, Zhu S
    Preliminary findings on the development of a predictive model for BLCA based on disulfidptosis-associated IncRNAs signature.
    BMC Urol. 2024;24:69.
    PubMed    
    Abstract available

  31. JIN P, Yang L, Liu Y, Huang J, et al
    Quantitative differentiation of non-invasive bladder urothelial carcinoma and inverted papilloma based on CT urography.
    BMC Urol. 2024;24:73.
    PubMed    
    Abstract available

  32. LIU FL, Zhang ZC, Zhou SL, Liu XL, et al
    Unlocking the Therapeutic Potential of LncRNA BLACAT1 in Hypopharynx Squamous Cell Carcinoma.
    Discov Med. 2024;36:546-558.
    PubMed    
    Abstract available

  33. YANG F, Nie J, Xiao F, Liu J, et al
    Impacts of enhanced recovery after surgery nursing interventions on wound infection and complications following bladder cancer surgery: A meta-analysis.
    Int Wound J. 2024;21:e14781.
    PubMed    
    Abstract available

  34. SHOJO K, Takeda T, Akita H, Suzuki T, et al
    Prediction of pathological up-staging after radical nephroureterectomy in patients with upper tract urothelial carcinoma.
    World J Urol. 2024;42:192.
    PubMed    
    Abstract available

  35. HE Y, Pan C, Zhang Y, Lv M, et al
    Nomogram for customized recurrence prediction in primary non-muscle-invasive bladder cancer based on routine blood and urine parameters.
    BMC Urol. 2024;24:67.
    PubMed    
    Abstract available

  36. ADELMANN TG, Ceausu AR, Gaje NP, Raica M, et al
    Endothelial cell proliferation and vascular patterns in urothelial carcinoma.
    Rom J Morphol Embryol. 2024;65:61-67.
    PubMed    
    Abstract available

  37. CHE X, Huang H, Wang W, Zhong L, et al
    Parastomal Hernia Following Ileal Conduit: Incidence, Risk Factors, and Health-Related Quality of Life.
    J Wound Ostomy Continence Nurs. 2024;51:126-131.
    PubMed    
    Abstract available

  38. WANG J, Yin Y, Ren X, Wang S, et al
    Electrospun nanofibrous mats loaded with gemcitabine and cisplatin suppress bladder tumor growth by improving the tumor immune microenvironment.
    J Mater Sci Mater Med. 2024;35:21.
    PubMed    
    Abstract available

  39. YANG G, Bai J, Hao M, Zhang L, et al
    Enhancing recurrence risk prediction for bladder cancer using multi-sequence MRI radiomics.
    Insights Imaging. 2024;15:88.
    PubMed    
    Abstract available

  40. XIE M, Zhou L, Li T, Lin Y, et al
    Targeting the KAT8/YEATS4 Axis Represses Tumor Growth and Increases Cisplatin Sensitivity in Bladder Cancer.
    Adv Sci (Weinh). 2024 Mar 25:e2310146. doi: 10.1002/advs.202310146.
    PubMed    
    Abstract available

  41. AUBERT C, Culty T, Zidane M, Bigot P, et al
    Antibiotic therapy impact on intravesical BCG therapy efficacy for high-risk localized bladder cancer treatment.
    Front Oncol. 2024;13:1240378.
    PubMed    
    Abstract available

  42. YANG XX, Wang C
    CircITGA7 regulates malignant phenotypes in bladder cancer cells via targeting miR-330-3p/KLF10 axis.
    Kaohsiung J Med Sci. 2024 Mar 25. doi: 10.1002/kjm2.12821.
    PubMed    
    Abstract available

  43. LIN L, Ning K, Xiang L, Peng L, et al
    SGLT2 inhibition and three urological cancers: Up-to-date results.
    Diabetes Metab Res Rev. 2024;40:e3797.
    PubMed    
    Abstract available

  44. REJEB SB, Elfekih S, Kouki N, Boulma R, et al
    Immunochemistry-based quantification of tumor-infiltrating lymphocytes and immunoscore as prognostic biomarkers in bladder cancer.
    J Egypt Natl Canc Inst. 2024;36:9.
    PubMed    
    Abstract available

  45. SHI Y, Xia W, Liu H, Liu J, et al
    Trihalomethanes in global drinking water: Distributions, risk assessments, and attributable disease burden of bladder cancer.
    J Hazard Mater. 2024;469:133760.
    PubMed    
    Abstract available

  46. SCHUBACH K, Niyonsenga T, Turner M, Paterson C, et al
    Identifying the supportive care needs of people affected by non-muscle invasive bladder cancer: An integrative systematic review.
    J Cancer Surviv. 2024 Mar 23. doi: 10.1007/s11764-024-01558.
    PubMed    
    Abstract available

  47. ZARZYCKA M, Kotula-Balak M, Gil D
    The mechanism of the contribution of ICAM-1 to epithelial-mesenchymal transition (EMT) in bladder cancer.
    Hum Cell. 2024 Mar 22. doi: 10.1007/s13577-024-01053.
    PubMed    
    Abstract available

  48. LI D, Wu R, Wang J, Ye J, et al
    A Prognostic Index Derived From LASSO-Selected Preoperative Inflammation and Nutritional Markers for Non-Muscle-Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2024 Feb 29:102061. doi: 10.1016/j.clgc.2024.
    PubMed    
    Abstract available

  49. CAO M, Cao Y, Xue S, Zhang Q, et al
    Therapeutic Benefits and Prognostic Value of a Model Based on 7 Immune-associated Genes in Bladder Cancer.
    Altern Ther Health Med. 2024 Mar 22:AT10582.
    PubMed    
    Abstract available

  50. TAN H, Li Y, Li J, Wang K, et al
    The Mechanism of miR-29 in Bladder Cancer Released by Exosomes into Brain Microglia to Promote M2 Polarization and Angiogenesis in Brain Metastasis of Bladder Cancer.
    Altern Ther Health Med. 2024 Mar 22:AT10593.
    PubMed    
    Abstract available

  51. SALEH M, Raffoul P, Akil A, Bassil P, et al
    Arab world's impact on bladder cancer research and opportunities for growth: A bibliometric review study.
    Medicine (Baltimore). 2024;103:e37554.
    PubMed    
    Abstract available

  52. DENG Y, Huang M, Deng R, Wang J, et al
    Immune checkpoint inhibitor-related adrenal hypofunction and Psoriasisby induced by tislelizumab: A case report and review of literature.
    Medicine (Baltimore). 2024;103:e37562.
    PubMed    
    Abstract available

  53. LIU Y, Pang Z, Wang J, Wang J, et al
    Multi-omics comprehensive analysis reveals the predictive value of N6-methyladenosine- related genes in prognosis and immune escape of bladder cancer.
    Cancer Biomark. 2024 Jan 25. doi: 10.3233/CBM-230286.
    PubMed    
    Abstract available


  54. Bladder cancer: An Update.
    Nursing. 2024;54:39-40.
    PubMed    


  55. PULLEN RL JR
    Bladder cancer: An Update.
    Nursing. 2024;54:27-39.
    PubMed    
    Abstract available

  56. YOGEETA F, Malik Z, Rauf SA, Devi M, et al
    Recurrent bladder leiomyoma: a case report.
    J Med Case Rep. 2024;18:173.
    PubMed    
    Abstract available

  57. ROSS J, Lavallee LT, Hickling D, van Walraven C, et al
    Development of the multivariate administrative data cystectomy model and its impact on misclassification bias.
    BMC Med Res Methodol. 2024;24:73.
    PubMed    
    Abstract available

  58. GIL-JIMENEZ A, van Dijk N, Vos JL, Lubeck Y, et al
    Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors.
    Nat Commun. 2024;15:2538.
    PubMed    
    Abstract available

  59. SMITH B, Khanna K, Pierce DP, Patel T, et al
    Chronic pelvic pain and dysmenorrhea disguising a rare submucosal leiomyoma of the urinary bladder.
    BMJ Case Rep. 2024;17:e258971.
    PubMed    
    Abstract available

  60. LI D, Wang J, Tuo Z, Yoo KH, et al
    Natural products and derivatives in renal, urothelial and testicular cancers: Targeting signaling pathways and therapeutic potential.
    Phytomedicine. 2024;127:155503.
    PubMed    
    Abstract available

  61. JHUANG JR, Lee CH, Chiang CJ, Chen CJ, et al
    Reduced burden of Arsenic-Related cancers after water mitigation in Taiwan.
    Environ Int. 2024;185:108542.
    PubMed    
    Abstract available

  62. KATOH M, Loriot Y, Brandi G, Tavolari S, et al
    FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions.
    Nat Rev Clin Oncol. 2024;21:312-329.
    PubMed    
    Abstract available

  63. DI GIACOMO AM, Schenker M, Medioni J, Mandziuk S, et al
    A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203).
    ESMO Open. 2024;9:102387.
    PubMed    
    Abstract available

  64. TEITSSON S, Brodtkorb TH, Kurt M, Patel MY, et al
    Challenges, considerations, and approaches for developing a cost-effectiveness model for the adjuvant treatment of muscle-invasive urothelial carcinoma: with a spotlight on nivolumab versus placebo.
    J Med Econ. 2024;27:473-481.
    PubMed    
    Abstract available

  65. GHOREIFI A, Shishido SN, Sayeed S, Courcoubetis G, et al
    Blood-based liquid biopsy: A promising noninvasive test in diagnosis, surveillance, and prognosis of patients with upper tract urothelial carcinoma.
    Urol Oncol. 2024;42:118.
    PubMed    
    Abstract available

  66. STROTHER M, Barlotta R, Uzzo R, Bloom E, et al
    Symptomatic and functional recovery after transurethral resection of bladder tumor: Data from ecological momentary symptom assessment.
    Urol Oncol. 2024;42:117.
    PubMed    
    Abstract available

  67. ALIMOHAMED N, Sridhar SS
    Combination strategies for advanced-stage urothelial carcinoma: a paradigm shift.
    Nat Rev Clin Oncol. 2024;21:255-256.
    PubMed    


  68. EGEN L, Wessels F, Quan A, Westhoff N, et al
    Maximizing efficiency and ensuring safety: Exploring the outcomes of 2 consecutive open radical cystectomies by the same team within a single surgical day.
    Urol Oncol. 2024;42:118.
    PubMed    
    Abstract available

  69. NUIJENS ST, van Osch FHM, van Hoogstraten LMC, Witjes JA, et al
    Longer time to radical cystectomy in patients treated with neoadjuvant chemotherapy is associated with worse oncological outcomes.
    Urol Oncol. 2024;42:117.
    PubMed    
    Abstract available

  70. POSADA JM, Yakirevich E, Kamat AM, Sood A, et al
    Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2.
    Mod Pathol. 2024;37:100424.
    PubMed    
    Abstract available

  71. TSUJI K, Kaneko M, Harada Y, Fujihara A, et al
    A Fully Automated Artificial Intelligence System to Assist Pathologists' Diagnosis to Predict Histologically High-grade Urothelial Carcinoma from Digitized Urine Cytology Slides Using Deep Learning.
    Eur Urol Oncol. 2024;7:258-265.
    PubMed    
    Abstract available

  72. TANDON M, Chakraborty S, Barkondaj B, Choudhury S, et al
    Role of multiparametric MRI in predicting muscle invasiveness in urinary bladder neoplasms with pathological correlations.
    Urologia. 2024;91:55-60.
    PubMed    
    Abstract available

  73. SINGH V, Sarangi SS, Bhirud DP, Sharma K, et al
    Assessing pentafecta outcomes post radical cystectomy: A tertiary care center study.
    Urologia. 2024;91:49-54.
    PubMed    
    Abstract available

  74. CHEVARRIA J, Ebad CA, Hamill M, Constandache C, et al
    Long-term renal function following radical cystectomy and ileal conduit creation.
    Ir J Med Sci. 2024;193:639-644.
    PubMed    
    Abstract available

  75. KEALEY J, Ip C, Davis ID, Sengupta S, et al
    The impact of multidisciplinary cancer meetings in guiding treatment intent in patients with upper tract urothelial carcinoma.
    Asia Pac J Clin Oncol. 2024;20:41-45.
    PubMed    
    Abstract available

  76. KLEBE M, Olbert PJ, Hofmann R, Barth PJ, et al
    [CpG-ODN instillation boosts ICAM-1 expression in an orthotopic murine UCC model: immunohistochemical evaluation of the local response to immunostimulatory DNA].
    Aktuelle Urol. 2024;55:154-160.
    PubMed    
    Abstract available

  77. AVUDAIAPPAN AP, Prabhakar P, Eldefrawy A, Caso J, et al
    CLO24-074: Impact of Neoadjuvant Chemotherapy on Survival and Pathological Response Among Octogenarians Who Underwent Radical Cystectomy for Muscle-Invasive Bladder Cancer.
    J Natl Compr Canc Netw. 2024;22.
    PubMed    


  78. AVUDAIAPPAN AP, Prabhakar P, Chundru S, Renshaw A, et al
    CLO24-064: Evaluation of the Reliability of mpMRI in Diagnosing Prostate Cancer Following Intravesical Bacillus Calmette Guerin Therapy for Bladder Cancer.
    J Natl Compr Canc Netw. 2024;22.
    PubMed    


  79. LIYANAGE T, Liyanage AH
    QIM24-194: A Cost Effective, Noninvasive Mutiomics Assay (BCDx) for Diagnostic Accuracy of Bladder Cancer Compares to the Gold Standard of Cytoscopy and Cytology.
    J Natl Compr Canc Netw. 2024;22.
    PubMed    


  80. PILALA KM, Kotronopoulos G, Levis P, Giagkos GC, et al
    MIR145 Core Promoter Methylation in Pretreatment Cell-Free DNA: A Liquid Biopsy Tool for Muscle-Invasive Bladder Cancer Treatment Outcome.
    JCO Precis Oncol. 2024;8:e2300414.
    PubMed    
    Abstract available

  81. PAN W, Liu X, Liu S
    ALYREF m5C RNA methylation reader predicts bladder cancer prognosis by regulating the tumor immune microenvironment.
    Medicine (Baltimore). 2024;103:e37590.
    PubMed    
    Abstract available

  82. LOPEZ VALCARCEL M, Barrado Los Arcos M, Ferri Molina M, Cienfuegos Belmonte I, et al
    Is trimodal therapy the current standard for muscle-invasive bladder cancer?
    Actas Urol Esp (Engl Ed). 2024 Apr 2:S2173-5786(24)00028.
    PubMed    
    Abstract available

  83. ZHANG W, Wang Y, Tang Q, Li Z, et al
    PAX2 mediated upregulation of ESPL1 contributes to cisplatin resistance in bladder cancer through activating the JAK2/STAT3 pathway.
    Naunyn Schmiedebergs Arch Pharmacol. 2024 Apr 4. doi: 10.1007/s00210-024-03061.
    PubMed    
    Abstract available

  84. SWINTON M, Devi A, Song YP, Hoskin P, et al
    Beyond surgery: bladder preservation and the role of systemic treatment in localised muscle-invasive bladder cancer.
    World J Urol. 2024;42:210.
    PubMed    
    Abstract available

  85. NIGLIO SA, Purswani JM, Schiff PB, Lischalk JW, et al
    Organ preservation in muscle-invasive urothelial bladder cancer.
    Curr Opin Oncol. 2024;36:155-163.
    PubMed    
    Abstract available

  86. COLAK R, Erdem GU, Kapar C, Gulturk I, et al
    Change in the neutrophil-lymphocyte ratio may predict early recurrence in operated bladder cancer.
    Asia Pac J Clin Oncol. 2024 Apr 4. doi: 10.1111/ajco.14065.
    PubMed    
    Abstract available

  87. LUO HM, Xiong YJ
    Comparing surgical site wound infection after laparoscopic and open radical cystectomies in patients with bladder cancer.
    Int Wound J. 2024;21:e14718.
    PubMed    
    Abstract available

  88. CAI T, Feng T, Li G, Wang J, et al
    Deciphering the prognostic features of bladder cancer through gemcitabine resistance and immune-related gene analysis and identifying potential small molecular drug PIK-75.
    Cancer Cell Int. 2024;24:125.
    PubMed    
    Abstract available

  89. LEARY JB, Enright T, Bakaloudi DR, Basnet A, et al
    Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer.
    Target Oncol. 2024 Apr 3. doi: 10.1007/s11523-024-01056.
    PubMed    
    Abstract available

  90. SLUSARCZYK A, Ismail H, Zapala L, Piecha T, et al
    Changes in the Urinary Microbiome After Transurethral Resection of Non-muscle-Invasive Bladder Cancer: Insights from a Prospective Observational Study.
    Ann Surg Oncol. 2024 Apr 3. doi: 10.1245/s10434-024-15198.
    PubMed    
    Abstract available

  91. TEKIN B, Erickson LA, Gupta S
    Secondary Involvement of the Urinary Bladder by Endometrial Carcinoma.
    Mayo Clin Proc. 2024;99:680-682.
    PubMed    


  92. LEE S, Yoon Y, Suh J, You D, et al
    Association of preoperative sarcopenia with the long-term prognosis of patients with bladder cancer undergoing radical cystectomy.
    J Cancer Res Clin Oncol. 2024;150:173.
    PubMed    
    Abstract available

  93. JIANG SC, Liao YG, Luo J, Hu D, et al
    Comparison of intravesical chemotherapy regimens after radical nephroureterectomy for upper tract urothelial carcinoma and analysis of risk factors for postoperative recurrence.
    Eur Rev Med Pharmacol Sci. 2024;28:2387-2395.
    PubMed    
    Abstract available

  94. ROSSER CJ
    Assessing the Causal Relationship between Waterpipe Smoking and Bladder Cancer.
    Cancer Epidemiol Biomarkers Prev. 2024;33:461-462.
    PubMed    
    Abstract available

  95. ZHOU J, Zhou R, Zhu Y, Deng S, et al
    Investigating the impact of regulatory B cells and regulatory B cell-related genes on bladder cancer progression and immunotherapeutic sensitivity.
    J Exp Clin Cancer Res. 2024;43:101.
    PubMed    
    Abstract available

  96. STANIORSKI CJ, Yu M, Sharbaugh D, Stencel MG, et al
    Predictors of persistent opioid use in bladder cancer patients undergoing radical cystectomy: A SEER-Medicare analysis.
    Urol Oncol. 2024 Apr 1:S1078-1439(24)00362-4. doi: 10.1016/j.urolonc.2024.
    PubMed    
    Abstract available

  97. JI Q, Ma F, Zhang X, Liu Y, et al
    Hsa_circ_0005320 affects cell proliferation and the cell cycle via the IGF2BP3/CDK2 axis in bladder cancer.
    Cell Signal. 2024 Mar 31:111154. doi: 10.1016/j.cellsig.2024.111154.
    PubMed    
    Abstract available

  98. OMURA M, Kosaka T, Kobayashi H, Shigeta K, et al
    ASO Author Reflections: Vasohibin-1 as a Biomarker for Chemotherapeutic Response in Patients with Advanced Bladder Cancer.
    Ann Surg Oncol. 2024 Apr 2. doi: 10.1245/s10434-024-15122.
    PubMed    


  99. BEN REJEB S, Kouki N, Ben Ghachem D, Khouni H, et al
    Prognostic significance of E-Cadherin and B-Catenin in non-muscle invasive bladder cancer.
    J Immunoassay Immunochem. 2024 Apr 1:1-10. doi: 10.1080/15321819.2024.2335154.
    PubMed    
    Abstract available

  100. LIN M, Xu X, Zhou X, Feng H, et al
    Sialylation on vesicular integrin beta1 determined endocytic entry of small extracellular vesicles into recipient cells.
    Cell Mol Biol Lett. 2024;29:46.
    PubMed    
    Abstract available

  101. KADORIKU F, Sasaki Y, Fukuta K, Nishiyama M, et al
    Robot-assisted intracorporeal ileal conduit urinary diversion: A two-center comparative study of Bricker versus Wallace ureteroileal anastomosis.
    Asian J Endosc Surg. 2024;17:e13307.
    PubMed    
    Abstract available

  102. CHENG M, Chen S, Li K, Wang G, et al
    CD276-dependent efferocytosis by tumor-associated macrophages promotes immune evasion in bladder cancer.
    Nat Commun. 2024;15:2818.
    PubMed    
    Abstract available

  103. YADOLLAHVANDMIANDOAB R, Jalalizadeh M, Dionato FAV, Buosi K, et al
    Clinical implications of single cell sequencing for bladder cancer.
    Oncol Res. 2024;32:597-605.
    PubMed    
    Abstract available

  104. HUANG Y, Lv Y, Yang B, Zhang S, et al
    Enhancing m(6)A modification of lncRNA through METTL3 and RBM15 to promote malignant progression in bladder cancer.
    Heliyon. 2024;10:e28165.
    PubMed    
    Abstract available

  105. SCHROECK FR, Grubb R, MacKenzie TA, Ould Ismail AA, et al
    Clinical Trial Protocol for "Replace Cysto": Replacing Invasive Cystoscopy with Urine Testing for Non-muscle-invasive Bladder Cancer Surveillance-A Multicenter, Randomized, Phase 2 Healthcare Delivery Trial Comparing Quality of Life During Cancer Surv
    Eur Urol Open Sci. 2024;63:19-30.
    PubMed    
    Abstract available

  106. MEAGHER M, Krause H, Elliott A, Farrell A, et al
    Characterization and impact of non-canonical WNT signaling on outcomes of urothelial carcinoma.
    Cancer Med. 2024;13:e7148.
    PubMed    
    Abstract available

  107. NAHAR R, Jinnah MSA, Karim SS, Alam MM, et al
    Expression of Cyclin D1 in Urothelial Carcinoma of Urinary Bladder and its Association with Tumour Grade.
    Mymensingh Med J. 2024;33:461-465.
    PubMed    
    Abstract available

  108. CAO Y, Zhu H, Li Z, Liu C, et al
    CT Image-Based Radiomic Analysis for Detecting PD-L1 Expression Status in Bladder Cancer Patients.
    Acad Radiol. 2024 Mar 30:S1076-6332(24)00138-7. doi: 10.1016/j.acra.2024.
    PubMed    
    Abstract available

  109. ACHARD V, Fournier B, D'Haese D, Krzystyniak J, et al
    Radiotherapy Combined with a Radiosensitizer for Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Carcinoma In Situ Bladder Cancer: An Open-label, Single-arm, Multicenter, Phase 2 European Organisation for Research and Treatment of Cancer Tri
    Eur Urol Oncol. 2024 Mar 30:S2588-9311(24)00084.
    PubMed    
    Abstract available

  110. LI L, Zhang J, Zhe X, Tang M, et al
    Prediction of histopathologic grades of bladder cancer with radiomics based on MRI: Comparison with traditional MRI.
    Urol Oncol. 2024 Mar 30:S1078-1439(24)00338.
    PubMed    
    Abstract available

  111. FENG X, Chen Z
    Case report and literature review of penile metastasis of bladder cancer.
    Asian J Surg. 2024 Mar 29:S1015-9584(24)00529.
    PubMed    


  112. CHEN Y, Jiao W, Wang Y, Liang Z, et al
    MITD1 deficiency leads to poor survival via tissue factor-mediated coagulation in bladder cancer.
    J Thromb Haemost. 2024 Mar 28:S1538-7836(24)00173.
    PubMed    
    Abstract available

  113. MONTGOMERY J, Lybbert D, Sana S, El-Zawahry A, et al
    Urinary bother, Urinalysis, and Two-Year Efficacy Follow-Up Results of Phase I Trial of Intravesical Bacillus Calmette-Guerin Combined with Intravenous Pembrolizumab in Recurrent or Persistent High-Grade Non-Muscle-Invasive Bladder Cancer after Previo
    Clin Genitourin Cancer. 2024;22:102059.
    PubMed    
    Abstract available

  114. JAIN NK, Tailang M, Thangavel N, Makeen HA, et al
    A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality.
    Acta Pharm. 2024;74:1-36.
    PubMed    
    Abstract available

  115. VERMEULEN R, Bodinier B, Dagnino S, Wada R, et al
    A prospective study of smoking-related white blood cell DNA methylation markers and risk of bladder cancer.
    Eur J Epidemiol. 2024 Mar 30. doi: 10.1007/s10654-024-01110.
    PubMed    
    Abstract available

  116. SASAKI Y, Izumi K, Fukuta K, Kadoriku F, et al
    Impact of lymph node dissection on surgical and oncological outcomes in patients undergoing robot-assisted radical cystectomy for bladder cancer: a multicenter retrospective study.
    J Robot Surg. 2024;18:141.
    PubMed    
    Abstract available

  117. HOHAGEN M, Sanchez L, Herbst AJ, Kahlig H, et al
    MANNosylation of Mesoporous Silica Nanoparticles Modifies TLR4 Localization and NF-kappaB Translocation in T24 Bladder Cancer Cells.
    Adv Healthc Mater. 2024 Mar 30:e2304150. doi: 10.1002/adhm.202304150.
    PubMed    
    Abstract available

  118. WASHINGTON SL 3RD, Lonergan PE, Odisho AY, Meng MV, et al
    Association of household net worth with healthcare costs after radical cystectomy using real-world data.
    Cancer Med. 2024;13:e7116.
    PubMed    
    Abstract available

  119. AHMADI S, Ambite I, Brisuda A, Hacek J, et al
    Similar immune responses to alpha1-oleate and Bacillus Calmette-Guerin treatment in patients with bladder cancer.
    Cancer Med. 2024;13:e7091.
    PubMed    
    Abstract available

  120. PORTEN SP, Wang EY, Vohra P, Carroll PR, et al
    Evaluation of URO17(R) to improve non-invasive detection of bladder cancer.
    Urol Oncol. 2024 Mar 28:S1078-1439(24)00345.
    PubMed    
    Abstract available

  121. LABIDI S, Meti N, Barua R, Li M, et al
    Clinical variables associated with immune checkpoint inhibitor outcomes in patients with metastatic urothelial carcinoma: a multicentre retrospective cohort study.
    BMJ Open. 2024;14:e081480.
    PubMed    
    Abstract available

  122. DING X, Jin Y, Shi X, Wang Y, et al
    TDO2 promotes bladder cancer progression via AhR-mediated SPARC/FILIP1L signaling.
    Biochem Pharmacol. 2024 Mar 27:116172. doi: 10.1016/j.bcp.2024.116172.
    PubMed    
    Abstract available

  123. LIN YH, Tsai HY, Wu CT
    From TURP to enucleation: navigating the complex relationship between BPH treatments and bladder cancer.
    World J Urol. 2024;42:203.
    PubMed    


  124. BIZZARRI FP, Scarciglia E, Russo P, Marino F, et al
    Elderly and bladder cancer: The role of radical cystectomy and orthotopic urinary diversion.
    Urologia. 2024 Mar 29:3915603241240644. doi: 10.1177/03915603241240644.
    PubMed    
    Abstract available

  125. BRODTKORB TH, Knight C, Kamgar F, Teitsson S, et al
    Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective.
    J Med Econ. 2024;27:543-553.
    PubMed    
    Abstract available

  126. SIMHAL RK, Simon DP, Wang KR, Shah YB, et al
    Perioperative and Complication Related Outcomes for Robotic-Assisted vs Open Radical Cystectomy: A Comparative National Surgical Quality Improvement Project Analysis.
    J Endourol. 2024;38:331-339.
    PubMed    
    Abstract available

  127. ZHANG KY, Hu JS, Liu XH
    Efficacy and safety of robot-assisted total cystectomy: A systematic review and meta-analysis.
    Asian J Surg. 2024;47:2028-2032.
    PubMed    


  128. CHEN BH, Hsieh SJ, Chiu B
    Non-functional bladder paraganglioma with urinary frequency: A case report.
    Asian J Surg. 2024;47:1990-1991.
    PubMed    


  129. XIN JH, Jiang B, Yuan YH, Zou XF, et al
    Primary diffuse large B-cell lymphoma of the urinary bladder: A case report.
    Asian J Surg. 2024;47:1930-1931.
    PubMed    


  130. HUANG P, Xin JH, Zou XF, Wu GQ, et al
    Isolated myeloid sarcoma in the urinary bladder: A cases report.
    Asian J Surg. 2024;47:1928-1929.
    PubMed    


  131. SU BY, Tan H, Bao JS, He QQ, et al
    Obstructive ureteral calculi and upper-tract urothelial carcinoma: A tale of two cases.
    Asian J Surg. 2024;47:1825-1826.
    PubMed    


  132. NISHIYAMA H, Yonese J, Kawahara T, Matsumoto R, et al
    TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor-Naive Locally Advanced or Metastatic Urothelial Carcinoma.
    Mol Cancer Ther. 2024;23:532-540.
    PubMed    
    Abstract available

  133. TANAKA S, Tokuhara Y, Ariyasu S, Morinishi T, et al
    Diagnostic Immunocytostaining with Peroxisome Proliferator-Activated Receptor-Gamma in Urine Cytology Samples.
    Acta Cytol. 2024;68:60-65.
    PubMed    
    Abstract available

  134. MONTOSA RODENAS P, Gomez Huertas M, Perez Rosillo MA, Lainez Ramos-Bossini AJ, et al
    Intravesical fat-fluid level as a warning sign of contained bladder perforation: Correlation between cystoscopy and computed tomography findings.
    Actas Urol Esp (Engl Ed). 2024;48:254-256.
    PubMed    


  135. TORIBIO-VAZQUEZ C, Gomez Rivas J, Amigo F, Carrion DM, et al
    Prevalence of urinary tract cancer in the Spanish cohort of the IDENTIFY study.
    Actas Urol Esp (Engl Ed). 2024;48:228-237.
    PubMed    
    Abstract available

  136. ZHANG M, Guo S, Gan S, Xu Q, et al
    "Internet Plus" continuous nursing for patients with advanced bladder cancer: A retrospective observational study.
    Medicine (Baltimore). 2024;103:e37822.
    PubMed    
    Abstract available

  137. ALHOZEEL B, Pandey SK, Shteinfer-Kuzmine A, Santhanam M, et al
    Silencing the Mitochondrial Gatekeeper VDAC1 as a Potential Treatment for Bladder Cancer.
    Cells. 2024;13:627.
    PubMed    
    Abstract available

  138. HE S, Xu J, Chen M, Li J, et al
    A meta-analysis of UCA1 accuracy in the detection of bladder cancer.
    Expert Rev Anticancer Ther. 2024 Apr 12. doi: 10.1080/14737140.2024.2342528.
    PubMed    
    Abstract available

  139. DU Y, Zhang X, Zhang H, Chen Y, et al
    [Retracted] Propofol modulates the proliferation, invasion and migration of bladder cancer cells through the miR?145?5p/TOP2A axis.
    Mol Med Rep. 2024;29:94.
    PubMed    
    Abstract available

  140. SLUSARCZYK A
    ASO Author Reflections: Changes in the Urinary Microbiome After Transurethral Resection of Nonmuscle-Invasive Bladder Cancer: Insights from a Prospective Observational Study.
    Ann Surg Oncol. 2024 Apr 11. doi: 10.1245/s10434-024-15248.
    PubMed    


  141. TANG L, Xu H, Wu T, Wu W, et al
    Advances in tumor microenvironment and underlying molecular mechanisms of bladder cancer: a systematic review.
    Discov Oncol. 2024;15:111.
    PubMed    
    Abstract available

  142. AVILEZ ND, Capibaribe DM, Reis LO
    Experimental and New Approaches for Bladder Preservation in Intermediate and High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC).
    Res Rep Urol. 2024;16:89-113.
    PubMed    
    Abstract available

  143. MAROOF H, Paramore L, Ali A
    Theories behind Bacillus Calmette-Guerin failure in high-risk non-muscle-invasive bladder cancer and update on current management.
    Cancer Pathog Ther. 2023;2:74-80.
    PubMed    
    Abstract available

  144. TOSI A, Parisatto B, Gaffo E, Bortoluzzi S, et al
    A paclitaxel-hyaluronan conjugate (ONCOFID-P-B) in patients with BCG-unresponsive carcinoma in situ of the bladder: a dynamic assessment of the tumor microenvironment.
    J Exp Clin Cancer Res. 2024;43:109.
    PubMed    
    Abstract available

  145. HONG S, Lee JH, Heo JY, Suh KJ, et al
    Impact of concurrent medications on clinical outcomes of cancer patients treated with immune checkpoint inhibitors: analysis of Health Insurance Review and Assessment data.
    J Cancer Res Clin Oncol. 2024;150:186.
    PubMed    
    Abstract available

  146. KIM JS, Lee J, Nguyen TT, Choi SY, et al
    Optimal timing for the first cystoscopic follow-up using time-to-treatment initiation analysis of oncologic outcomes in primary non-muscle invasive bladder cancer.
    Sci Rep. 2024;14:8440.
    PubMed    
    Abstract available

  147. IGLESIAS DE USSEL GALARRETA I, Queipo Gutierrez FJ
    Stromal osseous metaplasia in urothelial carcinoma of the bladder: An unusual and challenging feature. A case report.
    Rev Esp Patol. 2024;57:116-119.
    PubMed    
    Abstract available

  148. LI C, Lu B, Zhao Q, Lu Q, et al
    Development and validation of a clinical and ultrasound features-based nomogram for preoperative differentiation of renal urothelial carcinoma and central renal cell carcinoma.
    World J Urol. 2024;42:227.
    PubMed    
    Abstract available

  149. SU SW, Chen X, Wang G, Li P, et al
    A study on the significance of serine hydroxymethyl transferase expression and its role in bladder cancer.
    Sci Rep. 2024;14:8324.
    PubMed    
    Abstract available

  150. KURAL S, Jain G, Agarwal S, Das P, et al
    Urinary extracellular vesicles-encapsulated miRNA signatures: A new paradigm for urinary bladder cancer diagnosis and classification.
    Urol Oncol. 2024 Apr 8:S1078-1439(24)00361-2. doi: 10.1016/j.urolonc.2024.
    PubMed    
    Abstract available

  151. LIU K, Chen H, Li Y, Wang B, et al
    Autophagy flux in bladder cancer: Cell death crosstalk, drug and nanotherapetuics.
    Cancer Lett. 2024 Apr 7:216867. doi: 10.1016/j.canlet.2024.216867.
    PubMed    
    Abstract available

  152. HIRASAWA Y, Adachi T, Hashimoto T, Fukuokaya W, et al
    Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan.
    J Cancer Res Clin Oncol. 2024;150:182.
    PubMed    
    Abstract available

  153. SONG B, Kim JK, Lee H, Lee S, et al
    Evaluation of histological variants of upper tract urothelial carcinoma as prognostic factor after radical nephroureterectomy.
    World J Urol. 2024;42:225.
    PubMed    
    Abstract available

  154. ELSHEWY NE, Ramadan AA, Sameh WM, Eid ME, et al
    Does volumetric measurement of ADC values achieve higher diagnostic performance in bladder cancer MRI?
    Acta Radiol. 2024 Apr 9:2841851241241055. doi: 10.1177/02841851241241055.
    PubMed    
    Abstract available

  155. HASSAN M, Quereshi AH
    Paraganglioma of the urinary bladder: A case report.
    J Pak Med Assoc. 2024;74:570-572.
    PubMed    
    Abstract available

  156. NUSRAT NB, Rehman AU, Zafar N, Muhammad S, et al
    Challenges and technical aspects in the management of muscle invasive bladder cancer as retrograde radical cystectomy with ileal conduit.
    J Pak Med Assoc. 2024;74:513-518.
    PubMed    
    Abstract available

  157. PIJPERS OM, Boormans JL
    Disease progression in Bacillus Calmette Guerin unresponsive non-muscle invasive bladder cancer patients with carcinoma in situ, participating in clinical trials on bladder-sparing treatment.
    Transl Androl Urol. 2024;13:479-482.
    PubMed    


  158. KIM S, St-Laurent MP, Black P
    Biomarker challenges in the pursuit of personalized neoadjuvant chemotherapy for muscle-invasive bladder cancer: conclusions from SWOG S1314.
    Transl Androl Urol. 2024;13:458-462.
    PubMed    


  159. AGRAWAL S, Gupta A, Kapoor V, Rahul R, et al
    Predictors of Toxicity in a Randomized Study of Consolidation Chemoradiation Versus Observation After First Line Chemotherapy in Advanced Gall Bladder Cancers.
    Adv Radiat Oncol. 2024;9:101468.
    PubMed    
    Abstract available

  160. WEN X, Hou J, Chu Y, Liao G, et al
    Immunotherapeutic value of NUSAP1 associated with bladder cancer through a comprehensive analysis of 33 human cancer cases.
    Am J Cancer Res. 2024;14:959-978.
    PubMed    
    Abstract available

  161. WANG B, Zhou B, Chen J, Sun X, et al
    Type III interferon inhibits bladder cancer progression by reprogramming macrophage-mediated phagocytosis and orchestrating effective immune responses.
    J Immunother Cancer. 2024;12:e007808.
    PubMed    
    Abstract available

  162. HANNA P, Zabell J, Konety B, Warlick C, et al
    Perioperative complications and oncological outcomes of open versus robotic-assisted radical cystectomy: a propensity score-matched study.
    World J Urol. 2024;42:220.
    PubMed    
    Abstract available

  163. WANG J, Guo F, Zhang J, Chao J, et al
    Potential-resolved electrochemiluminescence for simultaneous determination of multiplex bladder cancer markers.
    Chem Commun (Camb). 2024 Apr 8. doi: 10.1039/d4cc00996.
    PubMed    
    Abstract available

  164. HAN Z, Ai J
    Editorial: Biomarkers and immunotherapy for genitourinary tumors.
    Front Immunol. 2024;15:1394170.
    PubMed    


  165. P VAN VALENBERG FJ, van der Heijden AG, Cutie CJ, Bhanvadia S, et al
    The Safety, Tolerability, and Preliminary Efficacy of a Gemcitabine-releasing Intravesical System (TAR-200) in American Urological Association-defined Intermediate-risk Non-muscle-invasive Bladder Cancer Patients: A Phase 1b Study.
    Eur Urol Open Sci. 2024;62:8-15.
    PubMed    
    Abstract available

  166. ZHANG X, Wang Y, Wang Y, Zhang J, et al
    MRI evaluation of vesical imaging reporting and data system for bladder cancer after neoadjuvant chemotherapy.
    Cancer Imaging. 2024;24:49.
    PubMed    
    Abstract available

  167. SANG J, Liu CK, Liu J, Luo GC, et al
    Jolkinolide B synergistically potentiates the antitumor activity of GPX4 inhibitors via inhibiting TrxR1 in cisplatin-resistant bladder cancer cells.
    Biochem Pharmacol. 2024;223:116194.
    PubMed    
    Abstract available

  168. LYU F, Huang S, Yan Z, He Q, et al
    CircUGGT2 facilitates progression and cisplatin resistance of bladder cancer through nonhomologous end-joining pathway.
    Cell Signal. 2024 Apr 5:111164. doi: 10.1016/j.cellsig.2024.111164.
    PubMed    
    Abstract available

  169. PULLEN L, Costa PF, Darr C, Hess J, et al
    Near-infrared fluorescence lymph node template region dissection plus backup lymphadenectomy in open radical cystectomy for bladder cancer using an innovative handheld device: A single center experience.
    J Surg Oncol. 2024 Apr 7. doi: 10.1002/jso.27618.
    PubMed    
    Abstract available

  170. ZHANG X, Liu Q, Yi K, Liu S, et al
    The Prognostic Value of the Combination of the Prognostic Nutritional Index and the Lymphocyte:Monocyte Ratio for the Prediction of Patients with Muscle-Invasive Bladder Cancer.
    Arch Esp Urol. 2024;77:164-172.
    PubMed    
    Abstract available

  171. REN H, Wang K, Liu C
    Analysis of the Clinicopathological Characteristics and Prognosis of Patients with Nonurothelial Bladder Cancer.
    Arch Esp Urol. 2024;77:148-157.
    PubMed    
    Abstract available

  172. ARIAFAR A, Kohansal E, Mousania A, Faghih Z, et al
    Natural Killer Cell Subsets in Tumor Draining Lymph Nodes of Patients with Bladder Cancer and Their Clinical Implications.
    Iran J Immunol. 2024;21.
    PubMed    
    Abstract available

  173. VOGL UM, Testi I, De Santis M
    Front-line Platinum Continues To Have a Role in Advanced Bladder Cancer.
    Eur Urol Focus. 2024 Apr 5:S2405-4569(24)00049-X. doi: 10.1016/j.euf.2024.
    PubMed    
    Abstract available

  174. WANG Z, Kwan ML, Haque R, Singh PK, et al
    Modifying Effects of Genetic Variations on the Association Between Dietary Isothiocyanate Exposure and Non-muscle Invasive Bladder Cancer Prognosis in the Be-Well Study.
    Mol Nutr Food Res. 2024 Apr 6:e2400087. doi: 10.1002/mnfr.202400087.
    PubMed    
    Abstract available

  175. ZENG X, Su H, Liu Z, Wang Y, et al
    Integrative analysis of the bladder cancer from a cell cycle NCAM1 perspective at both single cell and bulk resolution.
    Environ Toxicol. 2024 Apr 6. doi: 10.1002/tox.24260.
    PubMed    
    Abstract available

  176. CARROLL RA, Rice ES, Murphy WJ, Lyons LA, et al
    A chromosome-scale fishing cat reference genome for the evaluation of potential germline risk variants.
    Sci Rep. 2024;14:8073.
    PubMed    
    Abstract available

  177. ZHANG C, Xu X, Wang T, Lu Y, et al
    Clinical performance and utility of a noninvasive urine-based methylation biomarker: TWIST1/Vimentin to detect urothelial carcinoma of the bladder.
    Sci Rep. 2024;14:7941.
    PubMed    
    Abstract available

  178. AKBULUT D, Al-Ahmadie H
    Updates on Urinary Bladder Tumors With Neuroendocrine Features.
    Adv Anat Pathol. 2024;31:169-177.
    PubMed    
    Abstract available

  179. DENG H, Cheng F, Cheng S
    Comprehensive analysis of scRNA-seq and bulk RNA-seq reveal the characteristics of disulfidptosis and a prognostic signature in BLCA.
    Aging (Albany NY). 2024;16:5751-5771.
    PubMed    
    Abstract available

  180. MILOJEVIC B
    Reply to: Letter to the Editor for the Article "Prognostic Impact of Preoperative Thrombocytosis on Recurrence-Free Survival in Patients with Upper Tract Urothelial Carcinoma," by Urabe, Fumihik et al.
    Ann Surg Oncol. 2024;31:3565-3566.
    PubMed    


  181. URABE F, Tsuzuki S, Kimura T
    Letter to the Editor for the Article "Prognostic Impact of Preoperative Thrombocytosis on Recurrence-Free Survival in Patients with Upper Tract Urothelial Carcinoma".
    Ann Surg Oncol. 2024;31:3563-3564.
    PubMed    


  182. MONTEIRO FSM, Soares A, Mollica V, Leite CA, et al
    Efficacy of immune checkpoint inhibitors combinations as first-line systemic treatment in patients with advanced urothelial carcinoma: A systematic review and network meta-analysis.
    Crit Rev Oncol Hematol. 2024;196:104321.
    PubMed    
    Abstract available

  183. OTIS SU, Banna GL, Maniam A
    The association between paraneoplastic neurological syndromes (PNS) and urothelial carcinoma - A review of the literature.
    Crit Rev Oncol Hematol. 2024;196:104314.
    PubMed    
    Abstract available

  184. MIYAI K, Nakayama M, Minabe S, Ogata S, et al
    Implementation of The Paris System for Reporting Urine Cytology improves diagnostic accuracy of selective upper urinary tract cytology.
    Cancer Cytopathol. 2024;132:242-249.
    PubMed    
    Abstract available

  185. LORIOT Y, Petrylak DP, Rezazadeh Kalebasty A, Flechon A, et al
    TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes.
    Ann Oncol. 2024;35:392-401.
    PubMed    
    Abstract available

  186. CHO WC, Saade R, Nagarajan P, Aung PP, et al
    Nectin-4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotin.
    J Cutan Pathol. 2024 Jan 10. doi: 10.1111/cup.14579.
    PubMed    
    Abstract available

  187. TANG F, Wang X, Liu T, Wang H, et al
    Multiple Fluorescences in Situ Hybridization Status in Excreted Urine Improve Diagnostic Efficacy for Upper Urinary Tract Urothelial Carcinomas.
    Urol J. 2024;21:107-113.
    PubMed    
    Abstract available

  188. CEYHAN E, Mammadov E, Onder SC, Dogan HS, et al
    Fish: A Promising Screening Tool for Malignancy After Augmentation Cystoplasty?
    J Pediatr Surg. 2024;59:725-730.
    PubMed    
    Abstract available

  189. PANEBIANCO V, Briganti A, Boellaard TN, Catto J, et al
    Clinical application of bladder MRI and the Vesical Imaging-Reporting And Data System.
    Nat Rev Urol. 2024;21:243-251.
    PubMed    
    Abstract available

  190. GUPTA S, Andreev-Drakhlin A, Fajardo O, Fasso M, et al
    Platinum ineligibility and survival outcomes in patients with advanced urothelial carcinoma receiving first-line treatment.
    J Natl Cancer Inst. 2024;116:547-554.
    PubMed    
    Abstract available

  191. XU C, Xiong B
    Prognostic Nomograms for Patients with Primary Sarcomatoid Carcinoma of The Urinary Bladder: Based on The SEER Database.
    Urol J. 2024;21:87-97.
    PubMed    
    Abstract available

  192. SZYMANSKA B, Debowski J, Malkiewicz B, Piwowar A, et al
    Assessment of interleukin 17A and 23 in the course of bladder cancer and selected benign urological diseases.
    J Physiol Pharmacol. 2024;75.
    PubMed    
    Abstract available

  193. SATO R, Watanabe K, Matsushita Y, Watanabe H, et al
    Assessment of Therapeutic Effects of Combined Treatment With Cisplatin and Anti-mouse Programmed Death (PD)-1 Antibody in a Mouse Urothelial Cancer Model.
    Anticancer Res. 2024;44:1417-1423.
    PubMed    
    Abstract available

  194. FURUBAYASHI N, Minato A, Tomoda T, Hori Y, et al
    Change in the Neutrophil-to-Eosinophil Ratio After Avelumab Maintenance for Advanced Urothelial Carcinoma: The UROKYU Study.
    Anticancer Res. 2024;44:1675-1681.
    PubMed    
    Abstract available

  195. ENGLINGER B
    Molecular research in bladder cancer.
    Curr Opin Urol. 2024 Apr 12. doi: 10.1097/MOU.0000000000001181.
    PubMed    


  196. NOSSING C, Herek P, Shariat SF, Berger W, et al
    Advances in preclinical assessment of therapeutic targets for bladder cancer precision medicine.
    Curr Opin Urol. 2024 Apr 11. doi: 10.1097/MOU.0000000000001177.
    PubMed    
    Abstract available

  197. ABUFARAJ M, Al Karmi J, Bdeir A
    Is there a role for metastasis-directed therapy in bladder cancer?
    Curr Opin Urol. 2024 Apr 5. doi: 10.1097/MOU.0000000000001174.
    PubMed    
    Abstract available

  198. DUQUESNE I, de la Taille A
    Re: Erdafitinib in BCG-treated High-risk Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2024 Mar 26:S0302-2838(24)02206-1. doi: 10.1016/j.eururo.2024.
    PubMed    


  199. ZHOU Y, D'Andrea VD, Shanmugam SP, Stelter I, et al
    Activity of Enfortumab Vedotin and Sacituzumab Govitecan with Radiation in Preclinical Models of Bladder Cancer.
    Eur Urol. 2024 Mar 23:S0302-2838(24)02231-0. doi: 10.1016/j.eururo.2024.
    PubMed    


  200. BABJUK M
    Re: Erdafitinib in BCG-treated High-risk Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2024 Apr 9:S0302-2838(24)02262-0. doi: 10.1016/j.eururo.2024.
    PubMed    


  201. SAKURA Y, Yamashita R, Notsu A, Usui K, et al
    Effectiveness of adjuvant chemotherapy for patients who undergo radical cystectomy without neoadjuvant chemotherapy: A retrospective cohort study of 115 advanced bladder cancer patients with pathological lymph node classification.
    Int J Urol. 2024 Apr 12. doi: 10.1111/iju.15465.
    PubMed    
    Abstract available

  202. SILVA MEDEIROS M, Botelho de Carvalho LA, Alves M, Papoila A, et al
    Low Cubilin/Myeloperoxidase ratio as a promising biomarker for prognosis of high-grade T1 bladder cancer.
    Int Urol Nephrol. 2024 Mar 26. doi: 10.1007/s11255-024-03971.
    PubMed    
    Abstract available

  203. BERNARDINO RM, Wettstein M, Garisto J, Fleshner NE, et al
    Editorial comment to the paper: RE: low cubilin/myeloperoxidase's ratio as a promising biomarker for prognosis of high grade T1 bladder cancer.
    Int Urol Nephrol. 2024 Apr 2. doi: 10.1007/s11255-024-04035.
    PubMed    


  204. ZHU W, Wu L, Xie W, Zhang G, et al
    Comparison of morbidity and mortality after radical cystectomy between individuals older and younger than 80 years: a systematic review and meta-analysis.
    Int Urol Nephrol. 2024;56:1525-1535.
    PubMed    
    Abstract available

  205. KAY H, Silver SN, Smith AB, Basak R, et al
    Bladder Cancer Survivors Who Do Not Smoke Have Better Longitudinal Health Related Quality of Life Measures: An Assessment of the Comparative Effectiveness of Survivorship Health in Bladder Cancer (CEASE-BC) Study.
    J Urol. 2024 Apr 11:101097JU0000000000003964. doi: 10.1097/JU.0000000000003964.
    PubMed    
    Abstract available

  206. GARAZ R, Stuhler V, Stenzl A, Rottscholl R, et al
    Hemangioma of the Urinary Bladder: A Brief Narrative Review of Their Diagnosis, Histology, and Treatment Options.
    Urol Int. 2024;108:83-88.
    PubMed    
    Abstract available

  207. WALACH MT, Nitschke K, Gross-Weege M, Grosshans J, et al
    Cyclin A2 Expression as Predictive Biomarker in Muscle-Invasive Upper Tract Urothelial Carcinoma.
    Urol Int. 2024;108:128-136.
    PubMed    
    Abstract available

  208. CHEN LC, Yang HJ, Yu BH, Lee MS, et al
    Association of spironolactone use with risk of urinary tract cancer in the general population: A matched population-based cohort study.
    PLoS One. 2024;19:e0300391.
    PubMed    
    Abstract available


  209. Retraction: SATB1 Overexpression Regulates the Development and Progression in Bladder Cancer through EMT.
    PLoS One. 2024;19:e0301572.
    PubMed    



Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.


;